13th Oct 2015 09:14
LONDON (Alliance News) - Premaitha Health PLC said Tuesday that is assisting the Wolfson Institute of Preventive Medicine in launching an in-house antenatal reflex DNA screening service which will use Premaitha's DNA analysis platform.
In a statement ahead of the company's annual general meeting, Premaitha Chairman David Evans said that the service from Wolfson is a "good example of how we can help existing screening laboratories to adapt their methods and incorporate the opportunities of the new non-invasive prenatal screening test technology."
The DNA screening test estimates the risk of having a pregnancy with Down's syndrome, Edwards syndrome or Patau syndrome by analysing a sample of the mother's blood.
Premaitha is currently embroiled in a patent infringement case with Illumina Inc with regards to its IONA non-invasive prenatal test.
"We look forward to the coming year, in which we will continue to prioritise the commercialisation of our test and product development. We intend to further develop our business through closer collaboration with key opinion leaders, our platform and distribution partners. We will also continue to defend the company against the Illumina litigation with full vigour. We will not let it distract us from creating an exceptional genetic screening business delivering genuine clinical benefits to pregnant women across the world," Evans added.
Shares in Premaitha were up 3.1% at 13.15 pence Tuesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Premaitha Health